Medivolve Inc. (MEDVF)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Dec 12, 2025
Medivolve Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Operating Revenue | 0.9 | 0.69 | 1.39 | 86.82 | 10.58 | - |
| 0.9 | 0.69 | 1.39 | 86.82 | 10.58 | - | |
Revenue Growth (YoY) | - | -50.56% | -98.40% | 720.40% | - | - |
Cost of Revenue | 0.14 | 0.15 | 0.58 | 50.26 | 5.98 | - |
Gross Profit | 0.76 | 0.54 | 0.81 | 36.57 | 4.61 | - |
Selling, General & Admin | 3.63 | 3.95 | 13.93 | 24.14 | 13.16 | 2.05 |
Operating Expenses | 3.63 | 3.95 | 13.93 | 26.01 | 14.44 | 2.36 |
Operating Income | -2.87 | -3.41 | -13.11 | 10.56 | -9.83 | -2.36 |
Interest Expense | -0.24 | -0.29 | -0.24 | -0.48 | -4.68 | - |
Interest & Investment Income | - | - | 0 | 0.06 | 0.06 | 0.05 |
Earnings From Equity Investments | - | - | -0.09 | -0.31 | - | - |
Currency Exchange Gain (Loss) | -0.01 | 0.12 | -0.24 | 0.02 | 0.3 | -0.09 |
Other Non Operating Income (Expenses) | -0 | -0 | - | 0 | -0.28 | -0.07 |
EBT Excluding Unusual Items | -3.11 | -3.58 | -13.68 | 9.84 | -14.43 | -2.47 |
Gain (Loss) on Sale of Investments | 0.14 | 0.2 | -0.41 | -1.3 | -13.35 | -0.15 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.1 |
Asset Writedown | - | - | -0.5 | -6.54 | -0.14 | - |
Legal Settlements | - | - | - | -3.05 | - | - |
Other Unusual Items | - | -0.53 | 0.02 | 0.89 | -9.85 | - |
Pretax Income | -2.97 | -3.91 | -14.58 | -0.15 | -37.78 | -2.72 |
Income Tax Expense | - | - | - | 6.46 | - | - |
Earnings From Continuing Operations | -2.97 | -3.91 | -14.58 | -6.61 | -37.78 | -2.72 |
Earnings From Discontinued Operations | -11.79 | -12.75 | -3.79 | - | - | - |
Net Income to Company | -14.76 | -16.67 | -18.37 | -6.61 | -37.78 | -2.72 |
Minority Interest in Earnings | 0.28 | 0.21 | - | - | - | - |
Net Income | -14.48 | -16.46 | -18.37 | -6.61 | -37.78 | -2.72 |
Net Income to Common | -14.48 | -16.46 | -18.37 | -6.61 | -37.78 | -2.72 |
Shares Outstanding (Basic) | 27 | 27 | 27 | 19 | 7 | 2 |
Shares Outstanding (Diluted) | 27 | 27 | 27 | 19 | 7 | 2 |
Shares Change (YoY) | 0.01% | 0.01% | 39.81% | 189.58% | 192.76% | - |
EPS (Basic) | -0.54 | -0.61 | -0.68 | -0.34 | -5.66 | -1.19 |
EPS (Diluted) | -0.54 | -0.61 | -0.68 | -0.34 | -5.70 | -1.19 |
Free Cash Flow | -1.13 | -2.89 | 6.04 | -8.37 | -11.39 | -2.46 |
Free Cash Flow Per Share | -0.04 | -0.11 | 0.22 | -0.43 | -1.71 | -1.08 |
Gross Margin | 84.45% | 78.26% | 58.54% | 42.12% | 43.53% | - |
Operating Margin | -318.19% | -496.93% | -944.40% | 12.17% | -92.93% | - |
Profit Margin | -1605.03% | -2397.53% | -1322.72% | -7.61% | -356.96% | - |
Free Cash Flow Margin | -125.72% | -421.53% | 435.34% | -9.63% | -107.64% | - |
EBITDA | -2.87 | -3.28 | -12.98 | 11.56 | -9.72 | - |
EBITDA Margin | - | - | - | 13.31% | -91.88% | - |
D&A For EBITDA | 0 | 0.13 | 0.13 | 1 | 0.11 | - |
EBIT | -2.87 | -3.41 | -13.11 | 10.56 | -9.83 | -2.36 |
EBIT Margin | - | - | - | 12.17% | -92.93% | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.